Chordia Therapeutics Inc. (JP:190A) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc., a clinical-stage biotech company in Japan, has released a corporate research report through Fisco Corporation. The company is advancing its lead asset, rogocekib, a cancer therapy currently in Phase 1/2 trials in the US, and is working on other promising preclinical cancer treatments. This development could be of interest to investors tracking innovative cancer therapies and biotech advancements.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.